Archer develops early Biochip prototype
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Archer Materials Limited has announced the development of an early Biochip prototype for blood potassium sensing, marking a significant milestone in their technology advancement. The alpha prototype integrates the Biochip, test cartridge, and readout electronics, demonstrating stable operation and clinical-grade accuracy in potassium measurements. Archer is now progressing towards a beta prototype, expected to facilitate negotiations with MedTech companies for potential licensing deals. This development aims to enhance clinical workflows for potassium monitoring, particularly for patients with chronic kidney disease and heart failure.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Archer Materials Limited on 6ix
In the deck
Story so far
Earlier from Archer Materials
- Quarterly Activities/Appendix 4C Cash Flow Report
- AXE achieves readout milestone towards qubit demonstration
- AXE & CSIRO - Quantum Machine Learning for fraud detection
- Silicon Biochip meets performance and clinical requirements
- Archer and Emergence partner to pursue graphene quantum tech
Later from Archer Materials
- Appendix 4D and Half Year Financial Report
- Archer Materials Investor Webinar: First Half FY26 Update & Quantum Technology Developments
- Biochip advances toward beta prototype & clinical validation
- Archer strengthens pathway to quantum device manufacturing
- Biosensor beta prototype and manufacturing pathway advanced
Follow Archer Materials into a list and get an email when it puts out news.
Follow Archer Materials